SCHEMBL21774128

SCHEMBL21774128

Cc1cc(OCOC(=O)c2cccc(N(C)C)c2O)n(-c2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.44
▸ TP53 P04637 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ STAT1 P42224 1/20 0.43
▸ KMT2A Q03164 4/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ MDM2 Q00987 1/20 0.39
▸ NTRK1 P04629 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21775717 0.86 KDM5A (0.45) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774345 0.85 LMNA (0.35) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774333 0.85 NTRK1 (0.49) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774132 0.82 MAPT (0.42) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774330 0.80 KMT2A (0.59) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774344 0.79 MAPT (0.53) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21775658 0.78 KMT2A (0.50) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774298 0.77 MAPT (0.57) MAPTTP53LMNASTAT1KMT2A
SCHEMBL21774133 0.77 MAPT (0.49) MAPTLMNASTAT1KMT2ATDP1
SCHEMBL21774381 0.76 KMT2A (0.51) MAPTTP53LMNASTAT1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 — — US disclosed
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) 2023-07-04 — — US disclosed
WO-2020038279-A1 SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF 天津谷堆生物医药科技有限公司 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11692004-B2 Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof FARS2, GOT2, HADHB MAPT 856/4885TP53 695/4885LMNA 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback